- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01809379
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
July 7, 2022 updated by: Clemens Tempfer, Ruhr University of Bochum
Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial
This trial aims to assess efficacy and safety of an intraperitoneal, aerosol, high-pressure chemotherapy in women with recurrent ovarian cancer
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study aims to investigate the therapeutic efficacy of PIPAC using doxorubicin and cisplatin in women with recurrent ovarian cancer and disease progression with peritoneal carcinomatosis.
The primary objective of this study is to determine the Clinical Benefit Rate (CBR) according to RECIST criteria after three cycles of PIPAC with cisplatin and doxorubicin.
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
NRW
-
Bochum, NRW, Germany, 44623
- Ruhr University Bochum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- at least 2 lines of previous chemotherapy
- recurrent ovarian cancer
- patient is mobile
- informed consent
Exclusion Criteria:
- ileus
- necessity of parenteral nutrition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intraperitoneal chemotherapy
Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
|
intraperitoneal chemotherapy applied as an aerosol and under pressure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Rate
Time Frame: 6 months
|
The clinical benefit rate comprises complete remission, partial remission, and stable disease according to RECIST criteria.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety
Time Frame: 6 months
|
left heart ejection fraction, neurological status, laparoscopy complications intraoperative, laparoscopy complications postoperative until hospital discharge, re-admission to hospital, death
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tumor apoptosis assessment, videolaparoscopy assessment of response, CA 125 assessment of response
Time Frame: 6 months
|
various measures of response to therapy on the clinical, biochemical, and histological level
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Clemens Tempfer, MD, Runr University Bochum
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
March 8, 2013
First Submitted That Met QC Criteria
March 8, 2013
First Posted (Estimate)
March 12, 2013
Study Record Updates
Last Update Posted (Actual)
July 8, 2022
Last Update Submitted That Met QC Criteria
July 7, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease Attributes
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Recurrence
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cisplatin
- Doxorubicin
Other Study ID Numbers
- PIPAC-OV1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Ovarian Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedPseudomyxoma Peritonei | Recurrent Endometrial Carcinoma | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Leydig Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Ovarian Stromal Cancer | Recurrent Ovarian Germ Cell Tumor | Recurrent Fallopian Tube Cancer | Recurrent... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAstraZenecaTerminatedRecurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...United States
-
National Cancer Institute (NCI)CompletedRecurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity CancerCanada
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)WithdrawnOvarian Serous Cystadenocarcinoma | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Ovarian Germ Cell Tumor | Ovarian Papillary Serous Carcinoma | Recurrent Fallopian Tube CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedFallopian Tube Cancer | Recurrent Endometrial Carcinoma | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage IV Endometrial Carcinoma | Ovarian... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Stage III Vaginal Cancer | Stage IVA Cervical Cancer | Stage IVA Vaginal Cancer | Stage IVB Cervical Cancer | Stage IVB Vaginal Cancer | Stage IIIA Ovarian... and other conditionsUnited States
-
ImmunoVaccine Technologies, Inc. (IMV Inc.)Incyte CorporationActive, not recruitingRecurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Peritoneal CancerUnited States, Canada
-
CanariaBio Inc.Veristat, LLCActive, not recruitingPeritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Epithelial Cancer of Ovary | Recurrent Epithelial Ovarian Cancer | Recurrent Carcinoma of Ovary | Adenocarcinoma of OvaryUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube CancerUnited States
-
Mayo ClinicCompletedRecurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube CancerUnited States
Clinical Trials on chemotherapy with doxorubicin and cisplatin
-
Fujian Cancer HospitalNot yet recruitingNasopharyngeal CarcinomaChina
-
Clemens TempferCompleted
-
Air Force Military Medical University, ChinaUnknown
-
Vilnius UniversityNational Cancer Institute (NCI); Vilnius University Hospital Santaros KlinikosRecruitingGastric Cancer | Peritoneal CarcinomatosisLithuania
-
Sun Yat-sen UniversityActive, not recruitingLocal Advanced High Risk Nasopharyngeal CarcinomaChina
-
University Medical Center GroningenNRG Oncology; Dutch Cancer SocietyRecruitingVulvar Cancer | Sentinel Lymph Node | Lymph Node MetastasesUnited States, Netherlands
-
Zhao ChongCancer Institute and Hospital, Chinese Academy of Medical Sciences; Jiangxi... and other collaboratorsCompletedLocal Advanced High Risk Nasopharyngeal CarcinomaChina
-
University Hospital, GhentCompletedOvarian Cancer | Primary Peritoneal CancerBelgium
-
Cancer Hospital of Guangxi Medical UniversityUnknownEffects of ChemotherapyChina
-
Catholic University of the Sacred HeartCompletedOvarian Epithelial Cancer Recurrent | Platinum-resistantItaly